:internalReference - dapagliflozin | 461432-26-8
Spiacenti, non è stato trovato nessun prodotto con riferimento :internalReference, ma La invitiamo a verificare i seguenti prodotti simili:
Dapagliflozin
CAS:Formula:C21H25ClO6Purezza:≥ 98.0% (dried basis)Colore e forma:White to light-yellow powderPeso molecolare:408.87Dapagliflozin
CAS:Formula:C21H25ClO6Purezza:>95.0%(HPLC)Colore e forma:White to Light yellow powder to crystalPeso molecolare:408.88Dapagliflozin
CAS:Dapagliflozin (BMS-512148) is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.Formula:C21H25ClO6Purezza:99.5% - 99.93%Colore e forma:SolidPeso molecolare:408.87Ref: 10-F794039
1gPrezzo su richiesta5gPrezzo su richiesta10gPrezzo su richiesta25gPrezzo su richiesta100gPrezzo su richiesta10mgPrezzo su richiesta50mgPrezzo su richiesta100mgPrezzo su richiesta250mgPrezzo su richiestaDapagliflozin
CAS:<p>Stability Hygroscopic<br>Applications A sodium-glucose transporter 2 inhibitor.<br>References Kasichayanula, S. et al.: Diabetes, Obesity and Metabolism 13, 47 (2011)<br></p>Formula:C21H25ClO6Colore e forma:NeatPeso molecolare:408.87Dapagliflozin
CAS:Dapagliflozin is a sodium-glucose cotransporter subtype 2 (SGLT2) inhibitor that can be used in the treatment of diabetes mellitus type 2. SGLT2 is located in the proximal convoluted tubule and when it is inhibited the reabsorption of glucose into the kidneys is prevented and instead glucose is excreted in the urine. As a result glucose levels are reduced. Dapagliflozin is metabolized into to its inactive metabolite 3-O-glucuronide by the UGT1A9 enzyme present in the liver and the kidneys. In addition, dapagliflozin has been shown to cause weight loss and decrease the risk of cardiovascular events such as congestive heart failure.Formula:C21H25ClO6Purezza:Min. 98 Area-%Colore e forma:White Yellow PowderPeso molecolare:408.87 g/mol
